Evaluation of Single Nucleotide Variations in the Chronic Myeloid Leukemia (CML) Associated ABL1 Gene and the Efficacy of Tyrosine Kinase Inhibitors by Bioinformatics Tools
Bilecik Şeyh Edebali Üniversitesi Fen Bilimleri Dergisi · 31.05.2026 · 13 (1) · 1-16
DOI: 10.35193/bseufbd.1681493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bilecik Şeyh Edebali Üniversitesi Fen Bilimleri Dergisi, online erschienen am 31.05.2026. Verfasst von Ahmet Burak Doğanoğlu und 2 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
The ABL1 protein plays a critical role in the pathogenesis of chronic myeloid leukaemia (CML). In the treatment of CML, tyrosine kinase inhibitors (TKIs) targeting the ATP and myristoyl binding pockets of ABL1 are used. In this study, we aimed to evaluate the effects of missense variations in the ABL1 protein kinase domain on protein stability and TKI binding affinities. A total of 201 missense variations in the ABL1 protein kinase domain were examined, and 224 amino acid variations that could affect the ATP and myristoyl binding regions were analysed. Effects on protein stability were predicted using MAESTRO-web, I-Mutant 2.0, DUET, SDM, CUPSAT, and MUpro. Variants identified as destabilising in all tools were modelled using Swiss-Model DeepView, and binding affinities for Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Asciminib were calculated using AutoDock Vina with wild-type ABL1 as a reference. Functional effects were determined using PolyPhen2, PHD-SNP, PredictProtein, and PANTHER. Of the 224 variations, 74 were found to be destabilising by all tools. Of these variations, 29 negatively affected the binding affinity of six TKIs. The binding affinities of the wild-type protein are -10.7, -9.8, -10.6, -9.1, -10.8, and -11.1 kcal/mol, respectively. The I242T and V268M variations had the weakest binding values, while the A350T, M351V, Y353S, L354Q, I360T, and H361R variations were considered critical due to their proximity to the M351/F359 region. Most of the docking performed on the variant structures formed a hydrogen bond with the T315 amino acid. ABL1 variants may weaken TKI binding, thereby reducing treatment efficacy. Variants in the M351 and F359 region should be prioritised for clinical monitoring in terms of potential resistance mechanisms.
Zitieren
APA
Doğanoğlu, A. B., Kaman, T., & Karasakal, Ö. F. (2026). Evaluation of Single Nucleotide Variations in the Chronic Myeloid Leukemia (CML) Associated ABL1 Gene and the Efficacy of Tyrosine Kinase Inhibitors by Bioinformatics Tools. Bilecik Şeyh Edebali Üniversitesi Fen Bilimleri Dergisi, 13(1), 1-16. https://doi.org/10.35193/bseufbd.1681493
Vancouver
Doğanoğlu AB, Kaman T, Karasakal ÖF. Evaluation of Single Nucleotide Variations in the Chronic Myeloid Leukemia (CML) Associated ABL1 Gene and the Efficacy of Tyrosine Kinase Inhibitors by Bioinformatics Tools. Bilecik Şeyh Edebali Üniversitesi Fen Bilimleri Dergisi. 2026;13(1):1-16. doi:10.35193/bseufbd.1681493
BibTeX
@article{Doanolu2026,
author = {Doğanoğlu, Ahmet Burak and Kaman, Tuğba and Karasakal, Ömer Faruk},
title = {Evaluation of Single Nucleotide Variations in the Chronic Myeloid Leukemia (CML) Associated ABL1 Gene and the Efficacy of Tyrosine Kinase Inhibitors by Bioinformatics Tools},
journal = {Bilecik Şeyh Edebali Üniversitesi Fen Bilimleri Dergisi},
year = {2026},
volume = {13},
number = {1},
pages = {1--16},
doi = {10.35193/bseufbd.1681493}
}
EUVIMED